

Publications from The Sonya Slifka Longitudinal MS Study

(With links to abstracts, and full paper where available via open access)

1. [Access to and utilization of neurologists by people with multiple sclerosis](#) S. L. Minden, D. C. Hoaglin, L. Hadden, D. Frankel, T. Robbins and J. Perloff **Neurology** 2008;70;1141-1149.
2. [Access to health care for people with multiple sclerosis](#). Minden SL1, Frankel D, Hadden L, Hoaglin DC. **Mult Scler.** 2007 May;13(4):547-58. Epub 2007 Feb 9.
3. [ApoE Alleles, Depression and Positive Affect in Multiple Sclerosis](#) Julian LJ1, Vella L, Frankel D, Minden SL, Oksenberg JR, Mohr DC. **Mult Scler.** 2009 Mar;15(3):311-5.
4. [Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population](#) Tappenden P1, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD, Brown M. **Value Health.** 2009 Jul-Aug;12(5):657-65.
5. [Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study](#) Noyes K1, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. **Neurology.** 2011 Jul 26;77(4):355-63.
6. [Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study](#) Minden SL1, Frankel D, Hadden LS, Srinath KP, Perloff JN. *NeuroRehabilitation.* 2004;19(1):55-67.
7. [Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study](#) S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, J Outley **Mult Scler.** 2008 Jun;14(5):640-55.
8. [QUALITY OF LIFE IN PEOPLE WITH MULTIPLE SCLEROSIS: DATA FROM THE SONYA SLIFKA LONGITUDINAL MULTIPLE SCLEROSIS STUDY](#) Wu N1, Minden SL, Hoaglin DC, Hadden L, Frankel D.J **Health Hum Serv Adm.** 2007 Winter;30(3):233-67.
9. [The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics](#) Minden SL1, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. **Mult Scler.** 2006 Feb;12(1):24-38.
10. [Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?](#) Minden SL1, Kinkel RP2, Machado HT1, Levin JS3, Rosenthal MB4, Iezzoni LI5,6. **Mult Scler J Exp Transl Clin.** 2019 Feb 20;5(1):2055217318820888.